First, we performed Sulforhodamine B (SRB) toxicity assay with two mutant BRAF inhibitors vemurafenib and dabrafenib, and a MEK inhibitor selumetinib alone and in combination in PF49 and A375 melanoma cells (Fig. 3). The gene discussed is MAP2K7; the disease is melanoma.